Your search for nanoviricides returned 6 results

NanoViricides Raises $9.9M at 26% Discount

NanoViricides, Inc. (NNVCD) announced that it has raised $9,985,500 in a Registered Direct transaction. The common stock was sold at $3.50 per share, an approximate 26% discount to the market price ($4.76) of NNVCD at deal announcement. A series of 2,853,000 60-Month Warrants with an exercise price of $5.25 per share (10.29% premium) was issued to the investors in this transaction. Chardan Capital Markets and Midtown Partners acted as agents on the transaction. The transaction is expected to close by 09/13/2013.

Source: PlacementTracker

Posted on: September 11, 2013

NanoViricides Raises $6M in Conv Debt at 108% Premium

NanoViricides, Inc. (NNVC) announced that it has raised $6,000,000 in a Convertible Unsecured Debentures transaction. The fixed conversion price of the Convertible Unsecured Debentures is $1.00 per share, an approximate 108.25% premium to the market price ($0.48) of NNVC at deal announcement. The Company shall pay interest of 8% per annum plus additional interest upon Closing and each anniversary of the Closing.

Source: PlacementTracker

Posted on: February 1, 2013


NanoViricides Takes Short Seller Hit

NanoViricides (NNVC), a biotech company that has raised $42 million through PIPE and registered equity private placements in the last 12 months, including a $20 million registered direct offering managed by Midtown Partners and Chardan Capital Markets in late January, experienced a hit of up to 28% in its stock on Tuesday, Feb. 11, after an anonymous short seller published a research note questioning how company assets are being spent by executives. Growth Capital Investor reported in October on many of the issues raised in the Seeking Alpha article, which included discrepancies in their public filings. The company briefly halted the small cap stock mid-day and held a conference call on a small internet radio station called Yorba Media calling the article “baseless and inaccurate.”

NanoViricides, headed up by Eugene Seymour and Anil Diwan, claims to be creating special purpose nano-materials for viral therapy. The company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, oral and genital herpes, viral diseases of the eye including EKC and herpes keratitis, hepatitis C, rabies, Dengue fever, and Ebola virus, among others.